Angle Regulatory News (AGL)

ANGLE plc

("ANGLE" or the "Company")

FUNDRAISING

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that it has successfully completed a fundraising of up to £1.2 million (the "Fundraising") net of costs. Investors will acquire up to 1,715,717 new ordinary shares of 10p per share in the Company (the "Fundraising Shares") at a price of 70 pence per share representing a discount of 13.6% on the mid price of 81 pence per share at close of business on 25 January 2012.

The proceeds of the Fundraising are intended to not only provide funding for the revitalised Novocellus agreement with ORIGIO, announced today, but also to ensure that the Company has sufficient funding to complete development of the Parsortix cancer diagnostic product for the research market.

The Fundraising Shares will represent approximately 4.5% of the enlarged issued share capital of the Company and will rank pari passu in all respects with ANGLE's existing ordinary shares, including the right to receive and retain all dividends and other distributions declared, made or paid after admission of the Fundraising Shares to trading on AIM ("Admission"). The number of ANGLE ordinary shares in issue following Admission of the Fundraising Shares will be 37,824,559.

The Fundraising included both a direct subscription to the Company and a placing of new ordinary shares of 10p each in the Company (the "Placing") and was supported both by existing shareholders and new investors.

The allotment of the Fundraising Shares, which is under existing authorities, is conditional on, inter alia, admission of the Fundraising Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies. Application will be made by the Company for the Fundraising Shares to be admitted to AIM following receipt of Advance Assurance from HMRC of eligibility for EIS and VCT relief. Subject to completion of the Fundraising, it is expected that the Fundraising Shares to be issued to EIS and VCT qualifying investors will be admitted to trading on AIM and dealings will commence no earlier than 8:00am on 16 February 2012. Fundraising Shares issued to other investors will be admitted to trading on AIM and dealings will commence no earlier than 8:00am on 17 February 2012. An update will be provided once HMRC Advance Assurance has been received.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We are delighted that investors have demonstrated their continued support for the Company. The funds raised will both enable us to kick-start our Novocellus IVF embryo viability programme and continue the strong progress of our Parsortix cancer diagnostic product. This will further diversify our risks and increase the potential for shareholder returns."

For further information: